Hikma Pharmaceuticals (LON:HIK) Shares Cross Above 200 Day Moving Average - Time to Sell?

Key Points

• Hikma shares rose above their 200-day moving average, reaching GBX 1,635 before last trading at GBX 1,615, compared with a 200-day average of GBX 1,462.57.
• Analysts remain bullish: six firms rate the stock “Buy,” with a consensus price target of GBX 2,085.83. Recent target increases ranged from GBX 1,870 to GBX 2,100.
• The company has a £3.37 billion market capitalization and solid liquidity ratios, while insider Tobias Hestler recently purchased 7,500 shares at GBX 1,648, signaling confidence in the stock.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,462.57 and traded as high as GBX 1,635. Hikma Pharmaceuticals shares last traded at GBX 1,615, with a volume of 542,086 shares changing hands.

Analyst Ratings Changes

A number of research firms have issued reports on HIK. Citigroup increased their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Berenberg Bank boosted their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a "buy" rating in a report on Tuesday, August 11th. Jefferies Financial Group upped their price objective on Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the stock a "buy" rating in a research report on Tuesday, August 25th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The company's 50-day simple moving average is GBX 1,593.21 and its 200-day simple moving average is GBX 1,462.57. The stock has a market capitalization of £3.37 billion, a P/E ratio of 8.92, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66.

Insider Activity

In other news, insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. 22.04% of the stock is currently owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source